Gilead Sciences (GILD) Non-Current Deffered Revenue (2009 - 2013)

Gilead Sciences (GILD) has reported Non-Current Deffered Revenue for 5 consecutive years, with $22.0 million the latest figure, recorded in Q4 2013.

• For the quarter ending Q4 2013, Non-Current Deffered Revenue rose 7.05% year-over-year to $22.0 million; the trailing twelve-month figure through Dec 2013 stood at $22.0 million (up 7.05% YoY), and the FY2013 full-year result was $22.0 million, up 7.05% from the prior year.
• Non-Current Deffered Revenue retreated to $22.0 million in Q4 2013 per GILD's latest filing, from $25.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $53.4 million in Q2 2009 and bottomed at $20.5 million in Q4 2012.
• Historically, Non-Current Deffered Revenue has averaged $32.2 million across 5 years, with a median of $31.1 million in 2011.
• The sharpest annual moves came in 2012 and 2013: Non-Current Deffered Revenue slumped 39.96% in 2012, then increased 21.89% in 2013.
• Over 5 years, Non-Current Deffered Revenue stood at $43.0 million in 2009, then slipped by 23.66% to $32.8 million in 2010, then slipped by 2.97% to $31.9 million in 2011, then plunged by 35.58% to $20.5 million in 2012, then climbed by 7.05% to $22.0 million in 2013.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $22.0 million, $25.4 million, and $28.8 million for Q4 2013, Q3 2013, and Q2 2013 respectively.